Search Results for: DNA VACCINE TECHNOLOGY A Vaccine
Articles
Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy July 11, 2023
Akari Therapeutics, Plc recently announced updates on the development of long-acting PAS-nomacopan as a potential treatment for geographic atrophy (GA)....Valo Therapeutics & Texcell Announce Research Collaboration to Evaluate Immune Responses to PeptiCRAd-1 in Phase 1 Clinical Study June 13, 2023
Valo Therapeutics Oy recently announced a collaboration with global contract research organization, Texcell, to investigate immune responses to PeptiCRAd-1 in...Catalent Expands OneBio® Suite for Integrated Development, Manufacturing & Supply Across Biologic Modalities June 5, 2023
Catalent recently announced it has expanded its integrated development, manufacturing and supply solution, OneBio® Suite, across a range of biologic...Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform From Exacis Biotherapeutics May 2, 2023
Acquisition includes Exacis’ entire pipeline of engineered cell therapy programs for hematologic and solid tumors….
IMMUNOLOGY - Innovation Gathers Momentum Amid New Scientific & Technological Breakthroughs May 1, 2023
Patrick Larcier, PhD, says research is entering a new era in immunology with treatments for pathologies that previously had few or no options and looks at the latest trends and what is on the horizon for 2023 and beyond.
EXECUTIVE INTERVIEW - Ascendia Pharmaceuticals: Innovative Solutions to Challenging Problems May 1, 2023
Jim Huang, PhD, CEO and Founder of Ascendia Pharmaceuticals, discusses how his company expanded its people, capabilities, and facilities to meet and exceed customer expectations from early to late-state development and how this investment allows Ascendia to continue be an expert in sophisticated formulations, as well as cGMP sterile and non-sterile clinical trial and commercial manufacturing.
Aldevron Announces Expansion of mRNA Production Capability May 1, 2023
Aldevron recently announced it will expand its mRNA production capabilities to include lipid nanoparticle (LNP) encapsulation and aseptic fill-finish capabilities enabling...Aptamers Market is Expected to Reach $342 million April 27, 2023
The aptamers industry has been growing steadily in recent years, and is expected to continue to do so in the...WACKER, CordenPharma, LMU & HU Berlin Train Machine Learning Algorithm for the Formulation of RNA Actives March 31, 2023
Together with Munich’s Ludwig Maximilian University (LMU) and the Humboldt University of Berlin (HU Berlin), Wacker Chemie AG and CordenPharma...AUTOMATED SOLUTIONS - Automation & Shared Knowledge Pave the Way Into the Future March 1, 2023
Luca Valeggia says by no means is automation a novel concept for most research labs, but its swift advancement and expansion into new fields such as synthetic biology have shown us that we are only witnessing the start of what is possible.
IMUNON & Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination With Avastin in Advanced Ovarian Cancer February 27, 2023
IMUNON, Inc. and Break Through Cancer recently announced the commencement of patient enrollment in a collaboration to evaluate IMUNON’s IMNN-001...Catalent Launches New Service for End-to-End Supply Chain Case Management of Cell & Gene Therapies January 24, 2023
Catalent recently announced the launch of its new Case Management Service, which has been specifically designed to address the unique...Catalent to Expand Its Biologics Analytical Services With New Facility in North Carolina December 14, 2022
Catalent recently announced it is to establish a new biologics analytical center of excellence in Durham, within North Carolina’s Research...Catalent Opens One of the World’s Largest Commercial-Scale Cell Therapy Manufacturing Facilities at its European Center of Excellence for Cell Therapies in Belgium December 8, 2022
Catalent recently announced the completion and opening of a new commercial-scale cell therapy manufacturing facility at its European center of excellence for cell therapies in….
uniQure Announces FDA Approval of First Gene Therapy for Adults With Hemophilia B November 23, 2022
Historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy, and generates elevated and sustained factor IX levels….
Exelixis & Catalent Enter New License Agreement for Three Antibody-Drug Conjugate Programs With the Potential to Accelerate Exelixis’ Biologics Pipeline November 3, 2022
Exelixis, Inc. and Catalent, Inc. recently announced a new license agreement under which Catalent’s Redwood Bioscience subsidiary will grant Exelixis an exclusive license to three target programs with….
Catalent Expands Biologics Analytical Capabilities With New Laboratories at Center of Excellence in Kansas City, MO October 20, 2022
Catalent recently announced a $12-million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City,...RIGImmune Announces Acquisition of Antiviral Company Subintro September 16, 2022
RIGImmune Inc. recently announced the acquisition of Subintro, a biotechnology company specializing in the development and delivery of antiviral therapeutics...Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis June 28, 2022
Soligenix, Inc. recently announced the US FDA has cleared the Investigational New Drug (IND) application for a Phase 2a clinical...SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Understanding Critical Attributes Earlier in Development Leads to a More Robust Drug Product June 1, 2022
Contributor Cindy H. Dubin speaks with industry leaders on how drug sponsors and CDMOs are collaborating earlier, and highlights how third-party contractors are navigating material shortages and how the industry is shifting to address different therapeutic targets and molecules, such as mRNA.
